Oteseconazole (Vivjoa) for recurrent vulvovaginal candidiasis

Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-126.
No abstract available

Keywords: Brexafemme; Diflucan; Vivjoa; adverse effects; antifungals; dosage; drug interactions; efficacy; fluconazole; ibrexafungerp; lactation; oteseconazole; pregnancy; safety; vulvovaginal candidiasis.

MeSH terms

  • Administration, Oral
  • Antifungal Agents / adverse effects
  • Candidiasis, Vulvovaginal* / diagnosis
  • Candidiasis, Vulvovaginal* / drug therapy
  • Female
  • Humans

Substances

  • Antifungal Agents